A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
Part of paid clinical trials in Encinitas, California.
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Study ID
- NCT07526974
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Subcutaneous Fat
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- CBL-514 Injection — DRUGProvided as a ready for use injectable CBL-514 solution
- 0.9% Sodium Chloride — DRUGInjectable 0.9% Sodium Chloride solution as placebo
Study Details
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Key Dates
- Start date
- Oct 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Aug 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 320 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: CBL-514 injectionParticipants will receive CBL-514 administered up to 120 mL per treatment at a 4-weeks interval for up to 4 treatments.
- Placebo Comparator: Injectable 0.9% Sodium Chloride solutionParticipants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 4-week interval for up to 4 treatments.
Primary Outcome Measure
Percentage of participants achieving at least a 2-grade improvement from baseline on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and a clinically meaningful reduction in abdominal fat. [ Time Frame: From baseline to 4 weeks after final treatment ]
Central Contacts
- Shannon Wu+886-2-26971355
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Investigational Site 1 | Encinitas | California | 92024 | - |
| Investigational site 2 | Aventura | Florida | 33180 | - |
| Investigational Site 3 | Alpharetta | Georgia | 30005 | - |
| Investigational Site 4 | Hunt Valley | Maryland | 21030 | - |
| Investigational site 5 | Omaha | Nebraska | 68144 | - |
| Investigational site 6 | New York | New York | 10028 | - |
| Investigational Site 7 | Canal Winchester | Ohio | 43110 | - |
| Investigational site 8 | Nashville | Tennessee | 37215 | - |
| Investigational site 9 | Austin | Texas | 78759 | - |
| Investigational Site 10 | Arlington | Virginia | 22209 | - |
| Investigational Site 11 | Seattle | Washington | 98109 | - |
Find similar trials in Encinitas, CA
Related Studies
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatPHASE3 · Not Yet Recruiting · Caliway Biopharmaceuticals Co., Ltd. · Encinitas, California